Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467. The transaction involves a total consideration of up to $30m to Repare and directly influences the company’s cash status and upcoming shareholder arrangements. According to the terms, Gilead will pay Repare $25m upfront, subject to customary holdbacks and adjustments, and up to an additional $5m upon completion of certain technology transfer activities. On 14 November 2025, Repare ...

Core Viewpoint - Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences to acquire the experimental cancer therapy RP-3467, with a total transaction value of up to $30 million [1][3]. Group 1: Transaction Details - The agreement stipulates that Repare will receive up to $25 million in upfront payments from Gilead, with an additional potential of up to $5 million in subsequent payments upon completion of specific technology transfer-related matters [3]. - This upfront payment is expected to impact Repare's net cash position at the time of the merger completion [3]. Group 2: Impact on Stock Valuation - Following the announcement, the cash consideration per share for Repare in its previously agreed merger with XenoTherapeutics will increase to approximately $2.20, up from the prior offer of $1.82 per share [3]. Group 3: Clinical Development - Repare is advancing the POLAR Phase I clinical trial for RP-3467, assessing the safety and pharmacokinetic characteristics of the candidate drug when used in combination with the already marketed cancer drug olaparib [3]. - Olaparib is co-marketed by AstraZeneca and Merck under the brand name Lynparza [3].

Repare表示，这笔预付款将影响公司在并购交易完成时的净现金水平。受此影响，在其此前与 XenoTherapeutics达成的并购协议框架下，每股Repare股票在交易完成时可获得的现金对价将提高至约 2.20美元。此前，XenoTherapeutics同意以每股1.82美元现金收购 Repare。 目前，Repare正在推进RP-3467的POLAR Ⅰ期临床试验，评估该候选药物在多种肿瘤中与奥拉帕利 (olaparib)联合使用时的安全性和药代动力学特征。奥拉帕利是一款已上市的抗癌药物，由阿斯利康 (AZN.US)与默沙东(MRK.US)联合销售，商品名为Lynparza。 周三，加拿大生物科技公司Repare Therapeutics(RPTX.US)盘前一度大涨约20%。此前公司宣布，已与吉 利德科学(GILD.US)达成资产购买协议，收购其实验性抗癌疗法RP-3467，交易总价值最高可达3000万 美元。 根据协议条款，Repare将从吉利德获得最高2500万美元的预付款，并在完成特定技术转移相关事项后， 额外获得最多500万美元的后续付款。 来源：智通财经网 ...

目前，Repare正在推进RP-3467的POLAR Ⅰ期临床试验，评估该候选药物在多种肿瘤中与奥拉帕利 (olaparib)联合使用时的安全性和药代动力学特征。奥拉帕利是一款已上市的抗癌药物，由阿斯利康 (AZN.US)与默沙东(MRK.US)联合销售，商品名为Lynparza。 Repare表示，这笔预付款将影响公司在并购交易完成时的净现金水平。受此影响，在其此前与 XenoTherapeutics达成的并购协议框架下，每股Repare股票在交易完成时可获得的现金对价将提高至约 2.20美元。此前，XenoTherapeutics同意以每股1.82美元现金收购 Repare。 智通财经APP获悉，周三，加拿大生物科技公司Repare Therapeutics(RPTX.US)盘前一度大涨约20%。此 前公司宣布，已与吉利德科学(GILD.US)达成资产购买协议，收购其实验性抗癌疗法RP-3467，交易总 价值最高可达3000万美元。 根据协议条款，Repare将从吉利德获得最高2500万美元的预付款，并在完成特定技术转移相关事项后， 额外获得最多500万美元的后续付款。 ...

Repare表示，这笔预付款将影响公司在并购交易完成时的净现金水平。受此影响，在其此前与 XenoTherapeutics达成的并购协议框架下，每股Repare股票在交易完成时可获得的现金对价将提高至约 2.20美元。此前，XenoTherapeutics同意以每股1.82美元现金收购Repare。 周三，加拿大生物科技公司Repare Therapeutics(RPTX.US)盘前一度大涨约20%。此前公司宣布，已与吉 利德科学(GILD.US)达成资产购买协议，收购其实验性抗癌疗法RP-3467，交易总价值最高可达3000万 美元。 根据协议条款，Repare将从吉利德获得最高2500万美元的预付款，并在完成特定技术转移相关事项后， 额外获得最多500万美元的后续付款。 目前，Repare正在推进RP-3467的POLARⅠ期临床试验，评估该候选药物在多种肿瘤中与奥拉帕利 (olaparib)联合使用时的安全性和药代动力学特征。奥拉帕利是一款已上市的抗癌药物，由阿斯利康 (AZN.US)与默沙东(MRK.US)联合销售，商品名为Lynparza。 ...

Canadian stocks might open muted on the eve of Christmas. The stock will close early at 1.00 pm today. The Canadian will be completely closed for the Christmas on Thursday and Boxing day on Friday. The S&P/TSX composite Index closed 58.63 points or 0.18 percent at 32,058.73. Crude oil is gaining slightly, while gold is down 0.05 percent. In the Asian trading hours, the Canadian dollar strengthened against most major currencies and rose to a 5-month high of 1.3673 against the U.S. dollar and nearly a 2-week ...

Repare Therapeutics Inc. (RPTX) on Wednesday said it has reached an agreement with Gilead Sciences, Inc. to transfer its Pol? ATPase inhibitor, RP-3467, in a deal worth up to $30 million. Following the announcement, the company's shares rose more than 20% in pre-market trading.The consideration includes a $25 million upfront payment and an additional $5 million payment upon completion of specified transfer activities.RP-3467 is currently being evaluated in a Phase 1 study, both as a monotherapy and in comb ...

Core Viewpoint - Repare Therapeutics Inc. has entered into a definitive asset purchase agreement with Gilead Sciences, Inc. for the acquisition of its polymerase theta (Pol) ATPase inhibitor, RP-3467, indicating a strategic collaboration in oncology research and development [1] Company Summary - Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on developing innovative cancer therapies [1] - The acquisition of RP-3467 by Gilead is expected to enhance Gilead's oncology portfolio, leveraging its expertise in the field [1] Industry Summary - The oncology research and development sector is witnessing significant consolidation, as companies seek to combine resources and expertise to advance cancer treatment options [1] - The transaction highlights the growing interest in precision oncology and the potential for best-in-class therapies in the market [1]

Core Insights - Class Action Attorney Juan Monteverde's firm has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Group 1: Repare Therapeutics Inc. - Repare Therapeutics Inc. is being investigated regarding its sale to XenoTherapeutics, Inc. [1] - Upon closing, each Repare shareholder is expected to receive a cash payment of $1.82 per share, along with a non-transferable contingent value right for additional cash payments under certain conditions [1] Group 2: CNB Bank Shares, Inc. - CNB Bank Shares, Inc. is involved in a sale to HBT Financial, Inc. [2] - CNB shareholders will receive either 1.0434 shares of HBT common stock, $27.73 in cash per share, or a combination of both upon completion of the transaction [2] Group 3: Kimberly-Clark Corporation - Kimberly-Clark Corporation is merging with Kenvue Inc. [3] - Post-merger, Kimberly-Clark shareholders are expected to own approximately 54% of the combined company [3] Group 4: Kenvue Inc. - Kenvue Inc. is being sold to Kimberly-Clark Corporation [4] - Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share [4]

Merger Agreements and Investigations - Repare Therapeutics Inc. will be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp., with shareholders expected to receive US$1.82 per Common Share and a contingent value right for additional cash payments [2] - Axalta Coating Systems Ltd. is set to be acquired by Akzo Nobel N.V., where shareholders will receive 0.6539 shares of Akzo Nobel stock for each share of Axalta Coating common stock [4] - Blue Foundry Bancorp will be acquired by Fulton Financial Corporation, with each share of Blue Foundry common stock exchanged for 0.6500 shares of Fulton common stock, valuing the transaction at approximately $243 million or $11.67 per share [6] - Golden Entertainment, Inc. will be acquired in a sale-leaseback transaction, with stockholders receiving total consideration of $30.00, including a fixed exchange ratio of 0.902 shares of VICI common stock and a cash distribution of $2.75 per share [8] Investigations on Fiduciary Duties - Investigations are ongoing regarding whether the boards of Repare Therapeutics, Axalta Coating, Blue Foundry Bancorp, and Golden Entertainment breached their fiduciary duties by failing to conduct a fair process in the merger agreements [2][4][6][8]